Aaron Wealth Advisors LLC Sells 2,210 Shares of ResMed Inc. $RMD

Aaron Wealth Advisors LLC lessened its stake in shares of ResMed Inc. (NYSE:RMD) by 53.3% in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 1,938 shares of the medical equipment provider’s stock after selling 2,210 shares during the period. Aaron Wealth Advisors LLC’s holdings in ResMed were worth $467,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors have also made changes to their positions in RMD. SJS Investment Consulting Inc. boosted its holdings in shares of ResMed by 1,433.3% during the 3rd quarter. SJS Investment Consulting Inc. now owns 92 shares of the medical equipment provider’s stock valued at $25,000 after purchasing an additional 86 shares during the last quarter. ORG Partners LLC boosted its holdings in shares of ResMed by 181.6% during the 4th quarter. ORG Partners LLC now owns 107 shares of the medical equipment provider’s stock valued at $26,000 after purchasing an additional 69 shares during the last quarter. Imprint Wealth LLC bought a new position in shares of ResMed during the 3rd quarter valued at about $26,000. WFA of San Diego LLC bought a new position in shares of ResMed in the 2nd quarter valued at about $26,000. Finally, Sunbelt Securities Inc. bought a new position in shares of ResMed in the 3rd quarter valued at about $31,000. Institutional investors own 54.98% of the company’s stock.

Wall Street Analyst Weigh In

A number of research analysts recently commented on the stock. Stifel Nicolaus increased their price target on shares of ResMed from $260.00 to $265.00 and gave the company a “hold” rating in a report on Friday, January 30th. Wells Fargo & Company increased their price target on shares of ResMed from $265.00 to $270.00 and gave the company an “equal weight” rating in a report on Friday, January 30th. Weiss Ratings downgraded shares of ResMed from a “buy (b-)” rating to a “hold (c+)” rating in a report on Thursday, March 19th. Robert W. Baird set a $281.00 price target on shares of ResMed in a report on Friday, January 30th. Finally, UBS Group reaffirmed a “buy” rating and issued a $345.00 price target on shares of ResMed in a report on Friday, December 12th. One investment analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating and five have issued a Hold rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $298.82.

ResMed Stock Performance

Shares of NYSE:RMD opened at $227.86 on Friday. The firm has a market cap of $33.19 billion, a PE ratio of 22.54, a price-to-earnings-growth ratio of 1.53 and a beta of 0.93. The firm’s 50 day simple moving average is $244.16 and its 200-day simple moving average is $252.15. ResMed Inc. has a one year low of $202.00 and a one year high of $293.81. The company has a debt-to-equity ratio of 0.06, a quick ratio of 2.32 and a current ratio of 3.06.

ResMed (NYSE:RMD) last issued its earnings results on Friday, January 30th. The medical equipment provider reported $2.81 EPS for the quarter, topping analysts’ consensus estimates of $2.68 by $0.13. The business had revenue of $1.42 billion for the quarter, compared to analyst estimates of $1.40 billion. ResMed had a net margin of 27.53% and a return on equity of 25.20%. The company’s quarterly revenue was up 11.0% compared to the same quarter last year. During the same period last year, the company posted $2.43 earnings per share. As a group, equities analysts predict that ResMed Inc. will post 9.47 EPS for the current year.

ResMed Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Thursday, March 19th. Stockholders of record on Thursday, February 12th were given a dividend of $0.60 per share. The ex-dividend date of this dividend was Thursday, February 12th. This represents a $2.40 dividend on an annualized basis and a dividend yield of 1.1%. ResMed’s dividend payout ratio (DPR) is 23.74%.

Insider Activity at ResMed

In related news, CEO Michael J. Farrell sold 4,991 shares of ResMed stock in a transaction that occurred on Monday, February 9th. The shares were sold at an average price of $273.78, for a total transaction of $1,366,435.98. Following the transaction, the chief executive officer directly owned 466,223 shares of the company’s stock, valued at $127,642,532.94. This trade represents a 1.06% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. Also, Director Peter C. Farrell sold 2,000 shares of ResMed stock in a transaction that occurred on Wednesday, April 1st. The shares were sold at an average price of $225.00, for a total transaction of $450,000.00. The disclosure for this sale is available in the SEC filing. Over the last three months, insiders have sold 21,023 shares of company stock worth $5,230,857. 0.65% of the stock is currently owned by corporate insiders.

ResMed Company Profile

ResMed (NYSE: RMD) is a global medical device and cloud-connectivity company focused on improving outcomes for people with sleep-disordered breathing and chronic respiratory conditions. Founded in 1989, the company is headquartered in San Diego, California, and develops, manufactures and distributes a range of devices and software used by patients, clinicians and providers worldwide.

ResMed’s product portfolio centers on noninvasive ventilation and sleep therapy equipment, including continuous positive airway pressure (CPAP) and bilevel devices, masks and related accessories for the treatment of obstructive sleep apnea and other respiratory disorders.